Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-10
2007-04-10
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S313000, C514S359000, C514S370000, C514S372000, C514S377000, C514S378000, C514S406000, C546S143000, C546S159000, C548S371700, C548S244000, C548S233000, C548S212000
Reexamination Certificate
active
10886329
ABSTRACT:
Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.
REFERENCES:
patent: 3818024 (1974-06-01), Krenzer
patent: 4093624 (1978-06-01), Revankar et al.
patent: 4296237 (1981-10-01), Cragoe, Jr.
patent: 4432992 (1984-02-01), Cragoe, Jr. et al.
patent: 5103014 (1992-04-01), Musser et al.
patent: 5494925 (1996-02-01), Court et al.
patent: 6020357 (2000-02-01), Pinto et al.
patent: 6235786 (2001-05-01), Dai et al.
patent: 6294573 (2001-09-01), Curtin et al.
patent: 6319921 (2001-11-01), Cirillo et al.
patent: 6525046 (2003-02-01), Cirillo et al.
patent: 2001/0008898 (2001-07-01), Tomiyama et al.
patent: 2003/0181411 (2003-09-01), Bosch et al.
patent: 2003/0186221 (2003-10-01), Lockhart et al.
patent: 2156343 (1972-05-01), None
patent: 2341064 (1974-03-01), None
patent: 3406329 (1985-08-01), None
patent: 1115350 (1988-05-01), None
patent: 4302702 (1994-08-01), None
patent: 4337847 (1995-05-01), None
patent: 4343831 (1995-06-01), None
patent: 4414840 (1995-11-01), None
patent: 0021228 (1980-06-01), None
patent: 0021228 (1980-06-01), None
patent: 0025232 (1980-09-01), None
patent: 0025232 (1980-09-01), None
patent: 0031796 (1981-07-01), None
patent: 0031796 (1981-07-01), None
patent: 0739884 (1996-04-01), None
patent: 0739884 (1996-04-01), None
patent: 0867435 (1998-03-01), None
patent: 0867435 (1998-03-01), None
patent: 0956855 (1998-04-01), None
patent: 0956855 (1998-04-01), None
patent: 0927555 (1998-12-01), None
patent: 1281399 (2002-07-01), None
patent: 2337554 (1977-08-01), None
patent: 2396549 (1979-02-01), None
patent: 971307 (1961-03-01), None
patent: 1127875 (1967-03-01), None
patent: 2220206 (1990-01-01), None
patent: WO 9119708 (1991-12-01), None
patent: WO 9208693 (1992-05-01), None
patent: WO 9424095 (1994-10-01), None
patent: WO 9515954 (1995-06-01), None
patent: WO 9534540 (1995-12-01), None
patent: WO 9616046 (1996-05-01), None
patent: WO 9619477 (1996-06-01), None
patent: WO 9734900 (1997-09-01), None
patent: WO 9822103 (1998-05-01), None
patent: WO 9915164 (1999-04-01), None
patent: WO 9923093 (1999-05-01), None
patent: WO 9959959 (1999-11-01), None
patent: WO 0002851 (2000-01-01), None
patent: WO 0006550 (2000-02-01), None
patent: WO 0007980 (2000-02-01), None
patent: WO 0018738 (2000-04-01), None
patent: WO 0021927 (2000-04-01), None
patent: WO 0041698 (2000-07-01), None
patent: WO 0043384 (2000-07-01), None
patent: WO 0059506 (2000-10-01), None
patent: WO 0112621 (2001-02-01), None
patent: WO 0114372 (2001-03-01), None
patent: WO 0114372 (2001-03-01), None
patent: WO 0174771 (2001-10-01), None
patent: WO 0196298 (2001-12-01), None
patent: WO 0214291 (2002-02-01), None
patent: WO 0228835 (2002-04-01), None
patent: WO 0234727 (2002-05-01), None
patent: WO 0234727 (2002-05-01), None
patent: WO 0240458 (2002-05-01), None
patent: WO 02060869 (2002-08-01), None
patent: WO 02060876 (2002-08-01), None
patent: WO 03000189 (2003-01-01), None
patent: WO 2003005999 (2003-01-01), None
patent: WO 03053368 (2003-07-01), None
patent: WO 03059373 (2003-07-01), None
patent: WO 2003/068223 (2003-08-01), None
patent: WO 03072577 (2003-09-01), None
patent: WO 2004/113352 (2004-12-01), None
patent: WO 2005110994 (2005-11-01), None
Identification of Novel Inhibitors of BCR-ABL Tyrosine Kinase via Virtual Screening; Peng, Huang, Ql, Xie, Xu, Wang and Yang; Bioorganic & Medicinal Chemistry Letters 13 (2003) 3693-3699.
Implications of Protein Flexibility for Drug Discovery; Simon J. Teague; astrazeneca.com; REVIEWS.
The Conformational Plasticity of Protein Kinases; Huse and Kuriyan; Cell, vol. 109, pp. 275-282; May 3, 2002.
Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS: Structural Basis for Ligand-Induced Disordering of the Activation Loop; Wu, McNae, Kontopidis, McClue, McInnes, Stewart, Wang, Zheleva, Marriage, Lane, Taylor, Fischer, and Walkinshaw; Structure, vol. 11, pp. 399-410; Apr. 2003.
Molecular Recognition with Convergent Functional Groups. 6. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components; Askew, Ballester, Buhr, Jeong, Jones, Parris, Williams, and Rebek, Jr.; J. Am. Chem. Soc. 1989, 111, pp. 1082-1090.
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate; Regan, Breitfelder, Cirillo, Gilmore, Graham, Hickey, Klaus, Madwed, Moriak, Moss, Pargellis, Pav, Proto, Swinamer, Tong, and Torcellini; J. Med. Chem. 2002, 45, pp. 2994-3008.
The Sequence of the Human Genome; J. Craig Venter, et al; Science Magazine; Feb. 16, 2001; vol. 291; pp. 1304-1351 (including Erratum/post date Jun. 8, 2001), 1 pg.
Initial sequencing and analysis of the human genome; Nature/vol. 409; Feb. 15, 2001; pp. 860-921.
Copper-Catalyzed Coupling of Aryl Iodides with Aliphatic Alcohols; Wolter, Nordmann, Job, and Buchwald; Organic Letters 2002; vol. 4, No. 6, pp. 973-976.
First Non-ATP Competitive Glycogen Synthase Kinase 3 (GSK-3) Inhibitors: Thiadizolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease; Martinez, Alonso, Castro, Perez, and Moreno; J. Med. Chem. 2002, 45, pp. 1292-1299.
On the preparation of 1-aryl-2-heteroaryl- and 2-aryl-1-heteroaryl-pyrroles as useful building blocks for biologically interesting heterocycles; Almerico, Montalbano, Diana, Barraja, Lauria, Cirrincione, and Dattolo; Dipartimento Farmacochimico, Tossicologico e Biologico, Palermo, Italy; pp. 129-142.
QSAR and Molecular Modelling for a Series of Isomeric X-Sulfanilamido-1-phenylpyrazoles; Koch, Seydel, Gasco, Tironl, and Fruttero; Quant. Struct. Act. Relat. 12, pp. 373-382 (1993).
Disposition of 1-[3-Aminomethyl) phenyl]-N-(3-fluoro-2′-methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluomethyl)-1H-pyrazole-5-carboxamide (DPC 423) by Novel Metabolic Pathways. Characterization of Unusual Metabolites by Liquid Chromatography/Mass Spectrometry and NMR; Mutlib, Shockcor, Chen, Espina, Pinto, Orwat, Prakash, and Gan; Chem. Res. Toxicol. 2002, 15, pp. 48-62.
P450-Mediated Metabolism of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC 423) and Its Analogues to Aldoximes. Characterization of Glutathione Conjugates of Postulated Intermediates Derived from Aloximes; Mutlib, Chen, Espina, Shockcor, Prakash, and Gan; Chem. Res. Toxicol. 2002, 15, pp. 63-75.
Synthesis and Characterization of Conjugated Mono- and Dithiol Oligomers and Characterization of Their Self-Assembled Monolayers; Boer, Meng, Perepichka, Zheng, Frank, Chabal, and Bao; Langmuir 2003, 19, pgs. 4272-4284; 2003 American Chemical Society.
An evaluation of the effect of light stabilisers on the exterior durability of polyester powder coatings for the architectural market; Johnson, Parducci and Nascovilli; Surface Coatings International 1999 (3); pp. 134-141.
Synthesis and Spectral-Luminescence properties of Hetarylethylene Derivatives of 2,5-Diphenyloxazole and 2,5-Diphenyl-1,3,4-Oxadizole; Krasovitskii, Egorova, Afanasiadi, Lysova, Polyakov and Tsukerman; 1982 Plenum Publishing Corporation; pp. 461-465.
The Difluoromethylensulfonic Acid Group as a Monoanionic Phosphate Surrogate for Obtaining PTP1B Inhibitors; Leung, Grzyb, Lee, Meyer, Hum, Jia, Liu, and Taylor; Bioorganic & Medicinal Chemistry 10 (2002) pp. 2309-2323.
Abnormal Diels-Alder Reaction of 5-Alkoxythiazoles with Highly Reactive Dienophiles; 4-Phenyl-3H-1,2,4-triazole-3,5(4H)-dione, Diethyl Azodicarboxylate, and Diethyl Oxomalonate; Shi, Ibata, Suga, and Matsumoto; Bull. Chem. Soc. Jpn., 65, pp. 3315-3321 (1992).
Telomere Shortening and Growth Inhibition of Human Cancer Cells by Novel Synthetic Telomerase Inhibitors MST-312, MST-295, and MST-199; Seimiya, Oh-hara, Suzuki, Naasani, Shimazaki, Tsuchiya, and Tsuruo; Molecular Cancer Therapeutics; vol. 1, Jul. 2002, pp. 657-665.
The Synthesis of some Substituted Biphenyl-4-carboxylic Acids, 4-Biphenylylacetic Acids, and
Flynn Daniel L.
Petillo Peter A.
Deciphera Pharmaceuticals LLC
Hovey & Williams, LLP
Saeed Kamal A.
LandOfFree
Anti-inflammatory medicaments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-inflammatory medicaments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory medicaments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3783103